- Markets
- Healthcare
- VIMTALABS
VIMTALABS
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Vimta Labs Enters Into Business Transfer Agreement With Thyrocare Technologies
Aug 30 (Reuters) - Vimta Labs Ltd VIML.NS:
ENTERED INTO BUSINESS TRANSFER AGREEMENT WITH THYROCARE TECHNOLOGIES
TO SELL ITS DIAGNOSTICS, PATHOLOGICAL SERVICES BUSINESS TO THYROCARE
DEAL FOR 70 MILLION RUPEES
Source text for Eikon: ID:nBSE9YlpNx
Further company coverage: THYO.NS
(Reporting by VijayDattaram Malkar)
(([email protected];))
Aug 30 (Reuters) - Vimta Labs Ltd VIML.NS:
ENTERED INTO BUSINESS TRANSFER AGREEMENT WITH THYROCARE TECHNOLOGIES
TO SELL ITS DIAGNOSTICS, PATHOLOGICAL SERVICES BUSINESS TO THYROCARE
DEAL FOR 70 MILLION RUPEES
Source text for Eikon: ID:nBSE9YlpNx
Further company coverage: THYO.NS
(Reporting by VijayDattaram Malkar)
(([email protected];))
Vimta Labs Ltd- To Consider Amalgamation Of Emtac Laboratories With Co
Vimta Labs Ltd VIML.NS:
VIMTA LABS LTD- TO CONSIDER AMALGAMATION OF EMTAC LABORATORIES WITH CO
Source text for Eikon: ID:nBSE65dWTs
Further company coverage: VIML.NS
Vimta Labs Ltd VIML.NS:
VIMTA LABS LTD- TO CONSIDER AMALGAMATION OF EMTAC LABORATORIES WITH CO
Source text for Eikon: ID:nBSE65dWTs
Further company coverage: VIML.NS
India's Vimta Labs Sept-Quarter Consol Profit Falls
Oct 30 (Reuters) - Vimta Labs Ltd VIML.NS:
INDIA'S VIMTA LABS SEPT-QUARTER CONSOL PROFIT 63.3 MILLION RUPEES VERSUS 132.1 MILLION RUPEES
VIMTA LABS LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 734.1 MILLION RUPEES VERSUS 798.5 MILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: VIML.NS
(([email protected];))
Oct 30 (Reuters) - Vimta Labs Ltd VIML.NS:
INDIA'S VIMTA LABS SEPT-QUARTER CONSOL PROFIT 63.3 MILLION RUPEES VERSUS 132.1 MILLION RUPEES
VIMTA LABS LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 734.1 MILLION RUPEES VERSUS 798.5 MILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: VIML.NS
(([email protected];))
India's Vimta Labs March-Quarter Consol Profit Rises
May 3 (Reuters) - Vimta Labs Ltd VIML.NS:
MARCH-QUARTER CONSOL PROFIT 126.8 MILLION RUPEES VERSUS 118.3 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 818.2 MILLION RUPEES VERSUS 740.9 MILLION RUPEES
NAMES S P VASIREDDI AS EXECUTIVE CHAIRMAN
DIVIDEND 2 RUPEES PER SHARE
Further company coverage: VIML.NS
(([email protected];))
May 3 (Reuters) - Vimta Labs Ltd VIML.NS:
MARCH-QUARTER CONSOL PROFIT 126.8 MILLION RUPEES VERSUS 118.3 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 818.2 MILLION RUPEES VERSUS 740.9 MILLION RUPEES
NAMES S P VASIREDDI AS EXECUTIVE CHAIRMAN
DIVIDEND 2 RUPEES PER SHARE
Further company coverage: VIML.NS
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Vimta Labs do?
Founded in 1984, Vimta Labs Limited provides analytical, clinical, and preclinical services to life sciences industries, quality testing for food and beverage sectors, and environmental services globally.
Who are the competitors of Vimta Labs?
Vimta Labs major competitors are Krsnaa Diagnostics, Thyrocare Tech., Nidan Labs. & Health, Metropolis Health., Vijaya Diagnostic, Dr. Lal Pathlabs, Cupid. Market Cap of Vimta Labs is ₹2,182 Crs. While the median market cap of its peers are ₹4,209 Crs.
Is Vimta Labs financially stable compared to its competitors?
Vimta Labs seems to be less financially stable compared to its competitors. Altman Z score of Vimta Labs is 20.56 and is ranked 5 out of its 8 competitors.
Does Vimta Labs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Vimta Labs latest dividend payout ratio is 10.81% and 3yr average dividend payout ratio is 10.23%
How has Vimta Labs allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress
How strong is Vimta Labs balance sheet?
Balance sheet of Vimta Labs is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Vimta Labs improving?
The profit is oscillating. The profit of Vimta Labs is ₹61.37 Crs for TTM, ₹41.01 Crs for Mar 2024 and ₹48.17 Crs for Mar 2023.
Is the debt of Vimta Labs increasing or decreasing?
Yes, The debt of Vimta Labs is increasing. Latest debt of Vimta Labs is -₹16.17 Crs as of Sep-24. This is greater than Mar-24 when it was -₹32.14 Crs.
Is Vimta Labs stock expensive?
Yes, Vimta Labs is expensive. Latest PE of Vimta Labs is 35.55, while 3 year average PE is 25.8. Also latest EV/EBITDA of Vimta Labs is 19.35 while 3yr average is 11.47.
Has the share price of Vimta Labs grown faster than its competition?
Vimta Labs has given better returns compared to its competitors. Vimta Labs has grown at ~37.28% over the last 3yrs while peers have grown at a median rate of 0.32%
Is the promoter bullish about Vimta Labs?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Vimta Labs is 36.7% and last quarter promoter holding is 36.76%
Are mutual funds buying/selling Vimta Labs?
There is Insufficient data to gauge this.